Redeye is relieved to see that the CHMP reiterates its positive opinion of Lecanemab/Leqembi with no...
Redeye leaves a research update following Klaria Pharma’s recently published Q4 2024 report.
Björn Borg (“Björn Borg”, “the Company” or “the Group”) is a well-established and renowned company w...
Redeye shares its initial thoughts on Dala Energi’s Q4 report, where the main highlight of the quart...
Revenue growth was -7% in Q4 y/y by excluding the largest customer.
Redeye provides a research update following the Q4 report published by Initiator Pharma earlier toda...
EBITDA 25% above driven by lower marketing costs Reiterates launch of Doro pre-installed sim cards i...
Redeye shares its initial take on Physitrack’s Q4 results, which came in above our expectations in t...
Redeye comments on MindArk’s Q4 results, which came in softer than expected across the board.
Redeye comments on Maximum Entertainment’s Q4-results where topline came in somewhat softer than exp...
Redeye updates its view on Verve Group following its Q4 2024 report, which came in stronger than exp...
Redeye is initiating coverage of Insplorion, a sensor technology company focusing on hydrogen detect...
Solwers had already released a profit warning for Q4 2024 and the full year on 1 February.
Redeye updates on W5 following its Q4-results where topline was as expected while profitability was ...
STENOCARE A/S (STENOCARE or the “Company”) published on February 27th the Company’s Q4-report for 20...
